April 23, 2018 / 11:19 AM / 5 months ago

BRIEF-Sage Therapeutics Submits New Drug Application To U.S. FDA For Intravenous Brexanolone In The Treatment Of Postpartum Depression

April 23 (Reuters) - SAGE Therapeutics Inc:

* SAGE THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR INTRAVENOUS BREXANOLONE IN THE TREATMENT OF POSTPARTUM DEPRESSION

* SAGE THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR INTRAVENOUS BREXANOLONE IN THE TREATMENT OF POSTPARTUM DEPRESSION

* SAGE THERAPEUTICS - NDA SUBMISSION SUPPORTED BY DATA FROM HUMMINGBIRD PROGRAM Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below